Last reviewed · How we verify
NOV03
NOV03 is an investigational antiviral medication.
NOV03 is an investigational antiviral medication. Used for Treatment of COVID-19.
At a glance
| Generic name | NOV03 |
|---|---|
| Sponsor | Bausch & Lomb Incorporated |
| Drug class | nucleoside analog |
| Target | viral DNA polymerase |
| Modality | Small molecule |
| Therapeutic area | Infectious Diseases |
| Phase | Phase 3 |
Mechanism of action
NOV03 is a nucleoside analog that inhibits viral replication by interfering with viral DNA synthesis.
Approved indications
- Treatment of COVID-19
Common side effects
- Nausea
- Diarrhea
- Headache
Key clinical trials
- Effects of NOV03 on the Tear Film (PHASE4)
- Perfluorohexylcotane (NOV03) for the Treatment of Signs and Symptoms of Dry Eye Disease Associated With Meibomian Gland Dysfunction (Gobi Study) (PHASE3)
- Effect of NOV03 on Signs and Symptoms of Dry Eye Disease Associated With Meibomian Gland Dysfunction (Mojave Study) (PHASE3)
- Long-Term Safety and Tolerability of NOV03 (Perfluorohexyloctane) in Subjects Who Completed Trial NVU-003 (Kalahari Study) (PHASE3)
- Perfluorohexyloctane (NOV03) for the Treatment of Signs and Symptoms of Dry Eye Disease (DED) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- NOV03 CI brief — competitive landscape report
- NOV03 updates RSS · CI watch RSS
- Bausch & Lomb Incorporated portfolio CI